Biochimica et Biophysica Acta-Reviews on Cancer

Papers
(The H4-Index of Biochimica et Biophysica Acta-Reviews on Cancer is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting241
Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer192
Advances in clinical immunotherapy for gastric cancer188
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter173
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer159
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics158
Non-coding RNAs and potential therapeutic targeting in cancer143
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.130
Progress and challenges of immunotherapy in triple-negative breast cancer121
Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives113
Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside113
The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential102
HER2-targeted therapies in gastric cancer94
Tumor-associated neutrophils and neutrophil-targeted cancer therapies89
Understanding and advancement in gold nanoparticle targeted photothermal therapy of cancer87
Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy81
Metabolic reprogramming in renal cancer: Events of a metabolic disease76
The role of N6-methyladenosine mRNA in the tumor microenvironment75
Genomic instability, inflammatory signaling and response to cancer immunotherapy74
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal74
Targeting tumor-associated macrophages for cancer immunotherapy73
The RNA m6A writer METTL14 in cancers: Roles, structures, and applications69
GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment66
Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer65
DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer64
The clinical relevance of gene expression based prognostic signatures in colorectal cancer61
Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors61
Combinatorial therapy in tumor microenvironment: Where do we stand?58
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers58
Pharmacological significance of the non-canonical NF-κB pathway in tumorigenesis57
Targeting Bcl-2 for cancer therapy57
LOXL2 in cancer: regulation, downstream effectors and novel roles57
PTEN in osteosarcoma: Recent advances and the therapeutic potential55
Long non-coding RNAs and cancer metastasis: Molecular basis and therapeutic implications53
Immunotherapy for advanced hepatocellular carcinoma, where are we?53
Non-mitotic functions of polo-like kinases in cancer cells52
CCR7 as a therapeutic target in Cancer52
Cyclin-dependent kinases in DNA damage response50
SOX9: An emerging driving factor from cancer progression to drug resistance49
Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression49
SOS GEFs in health and disease48
Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy48
The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer48
Nerve input to tumours: Pathophysiological consequences of a dynamic relationship47
The emerging role of miRNA clusters in breast cancer progression46
Recent advances in organoid development and applications in disease modeling46
0.076832056045532